Proteins and Peptides
6 March 2013
Tarix Pharmaceuticals’ Peptide Technology Stimulates Revascularization Following Ischemia26 February 2013
Baxter Submits Application for FDA Approval of FEIBA NF for Prophylactic Use in Hemophilia A and B Patients with Inhibitors25 February 2013
Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI25 February 2013
Merck Serono: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma24 February 2013
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS (peginesatide) Injection20 February 2013
Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer20 February 2013
C3 Jian Completes C16G2 Phase 1 Clinical Study Enrollment19 February 2013
Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease15 February 2013
ATryn Antithrombin (Recombinant) Prevents Venous Thromboembolic Events in Pregnant Patients with Hereditary Antithrombin Deficiency14 February 2013
The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis14 February 2013
Positive Data From Celldex’s Phase 1 Study of CDX-301 Support Initiation of Pilot Study in Hematopoietic Stem Cell Transplantation14 February 2013
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin12 February 2013
Critical Pharmaceuticals Announces Successful Completion of Second Clinical Trial on CP024 Intranasal Growth Hormone11 February 2013
Synageva BioPharma(TM) Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL Deficiency7 February 2013
Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference6 February 2013
Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers6 February 2013
Inspiration Biopharmaceuticals and Ipsen Complete Sale Process for All Hemophilia AssetsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports